We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Protective Antibodies for Malaria Identified by New Blood Test

By Labmedica staff writers
Posted on 13 Mar 2008
The malaria pathogen Plasmodium falciparum carries poisonous sugar molecules called glycosylosphatidylinositols (GPIs) on its surface that can be individually identified. More...
These sugar molecules are the dominant malarial toxins responsible for several pathologic processes associated with severe malaria. A person's immune system can form antibodies against these sugar molecules on the malaria pathogen, which protect against serious illness.

Blood samples taken from adults living in areas of Africa where malaria is endemic contain specific antibodies against particular GPIs. While infection is still possible despite the antibodies, the consequences are less serious. The immune system recognizes the poisonous sugar molecules as foreign bodies and blocks their toxic impact. Not living in high-risk areas, Europeans lack these antibodies. As soon as Europeans are infected with malaria, the number of antibodies increases significantly. Subsequently, there is a direct link between the amount of antibodies and protection against the disease.

A new blood test enables these antibodies to be detected. The method uses 64 pads comprising pinpoint dots affixed to glass slides. Every pad consists of several tiny heaps of different GPIs in varying concentrations. When blood serum is administered to such a pad, antibodies specifically bind to certain sugar molecules. Dyes then reveal to which GPIs the antibodies have become attached.

A chip developed in the laboratory of Prof. Peter Seeberger by a team of ETH Zurich and Swiss Tropical Institute (Zurich, Switzerland) scientists can use minute quantities of blood serum and sugar molecules to determine whether someone has formed particular antibodies against various GPIs. Large amounts of very pure GPIs can be produced synthetically in a laboratory, as the team demonstrated previously.

Using the information obtained from the chip, scientists can produce the specific sugar molecules that the immune system has to recognize. The findings should contribute to developing a sugar-based malaria vaccine and would be particularly beneficial to children in malaria-infested regions.

A report of the team's work was published online in the journal Nature Chemical Biology on March 2, 2008.


Related Links:
Swiss Tropical Institute

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.